タシマ ユウコ   Tashima Yuko
  田嶋 裕子
   所属   産業医科大学病院  診療科 呼吸器・胸部外科
   職種   助教
論文種別 症例報告
言語種別 英語
査読の有無 査読あり
表題 Programmed death-ligand 1 (PD-L1) expression in pleomorphic carcinoma of the lung.
掲載誌名 正式名:Journal of surgical oncology
略  称:J Surg Oncol.
ISSNコード:1096-9098
掲載区分国外
巻・号・頁 0(0),0-0頁
著者・共著者 Imanishi N, Hirai A, Yoneda K, Shimajiri S, Kuwata T, Tashima Y, Takeuchi M, Iwai Y, Ichiki Y, Tanaka F.
発行年月 2018/03
概要 Abstract
BACKGROUND AND OBJECTIVES:
Pulmonary pleomorphic carcinoma (PPC) is a rare and aggressive subtype of lung cancer. Programmed cell death-ligand 1 (PD-L1) expression may be induced in a variety of malignant tumors, but its prognostic implication in PPC remains unclear.
METHODS:
Twenty-six patients with surgically resected PPC were retrospectively reviewed. Immuno-histochemical staining was used to detect PD-L1 expression, and PD-L1 status was classified into "high" or "low" according to the percentage of tumor cells (TCs) expressing PD-L1 (tumor proportion score, TPS).
RESULTS:
PD-L1 expression was positive in 20 (76.9%) patients at the cut-off TPS value of 1%. A receiver-operating characteristic (ROC) analysis showed that the optimal cut-off value was 15% for prediction of cancer-specific death with the area under ROC curve of 0.701 (P = 0.107). High PD-L1 expression was associated with a favorable overall survival (100% vs 45.9% at 5 years; P = 0.046) as well as a favorable cancer-specific survival (88.9% vs 37.5% at 5 years; P = 0.012). A multivariate analysis indicated a trend toward a favorable prognosis associated with high PD-L1 expression (hazard ratio [HR], 0.254 [95% confidence interval, 0.054-1.200]; P = 0.084).
DOI 10.1002/jso.25041
PMID 29601633